Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs MMF for GVHD Prophylaxis in Haplo-HSCT
NCT04838704Completed
- Sponsor
- Zhejiang University
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ruxolitinib in graft-versus-host disease (GVHD) (2 arms), sponsored by Zhejiang University. Primary endpoint: 100-day cumulative II-IV aGVHD incidence after HSCT. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04838704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838704.